accuzide forte 20 mg/12,5 mg
pfizer manufacturing deutschland gmb - germania - combinatii (quinaprilum+hydrochlorothiazidum) - compr. film. - 20mg/12,5mg - combinatii de inhibitori ai e.c.a. inhibitori ai enzimei de conversie si diuretice - combinati
accuzide forte plus 20 mg/25 mg
pfizer manufacturing deutschland gmb - germania - combinatii (quinaprilum+hydrochlorothiazidum) - compr. film. - 20mg/25mg - combinatii de inhibitori ai e.c.a. inhibitori ai enzimei de conversie si diuretice - combinati
genotropin 16 ui/ml (5,3 mg/ml)
pfizer manufacturing belgium nv - belgia - somatropinum - pulb.+solv. pt. sol. inj. - 16ui/ml(5,3mg/ml) - hormoni ai lobului hipofizar anterior si analogi hormon somatotrop si agonisti ai acestuia
xalatan 50 µg/ml
pfizer manufacturing belgium n.v. - belgia - latanoprostum - picaturi oft., sol. - 50µg/ml - antiglaucomatoase si miotice analogi de prostaglandine
mylotarg
pfizer europe ma eeig - gemtuzumab ozogamicin - leucemie, mieloidă, acută - agenți antineoplazici - numele de mylotarg este indicat pentru terapia combinată cu daunorubicin (dnr) și citarabină (arac) pentru tratamentul pacienților de vârsta 15 ani și mai sus, cu netratați anterior, de novo, cd33-pozitiv leucemie mieloidă acută (aml), cu excepția leucemie acută promielocitară (lap).
accupro 10 mg
pfizer manufacturing deutschland gmbh - germania - quinaprilum - compr. film. - 10mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
accupro 20 mg
pfizer manufacturing deutschland gmbh - germania - quinaprilum - compr. film. - 20mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
accupro 5 mg
pfizer manufacturing deutschland gmbh - germania - quinaprilum - compr. film. - 5mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
zyvoxid 100 mg/5 ml
pfizer service company bv - belgia - linezolidum - gran. pt. susp. orala - 100mg/5ml - alte antibacteriene alte antibacteriene
bimzelx
ucb pharma s.a. - bimekizumab - psoriazis - imunosupresoare - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.